Trial Profile
A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs MK 7145 (Primary) ; Furosemide; Torasemide
- Indications Cardiovascular disorders; Heart failure
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 15 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record as reported by ClinicalTrials.gov record.
- 08 Apr 2014 The number of treatment arms changed from 5 to 7 (additional drug added- Torasemide, deleted-Placebo), patient sample size changed from 18 to 26 and previously mentioned primary outcomes (AUC and Cmax) are presently the secondary outcomes for this trial.